Mesenchymal Stem Cell Differentiation via Exogenous miRNA

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for generating oligodendrocytes for treating nerve diseases and disorders, such as multiple sclerosis, face challenges in achieving complete restoration of neurological deficits due to limitations in obtaining large numbers of myelinating cells for transplantation and incomplete remyelination.

Innovation Solution

The method involves contacting mesenchymal stem cells with specific exogenous miRNAs like miR-145, miR-125b, miR-128, and miR-30d to induce oligodendrocytic differentiation, and downregulating connective tissue growth factor (CTGF) to promote the generation of oligodendrocyte-like cells, which can be transplanted to treat central nervous system disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If mesenchymal stem cells are used for generating oligodendrocytes, then the source of cells is easily accessible and autologous, but the number of myelinating cells obtained is limited

Engineering Contradiction:

Improveease of cell source acquisitionVSAvoidnumber of myelinating cells

Core Design Contradiction:

Ease of manufactureVSQuantity of substance

Solution Approach 1:

The patent applies parameter changes by using specific miRNA molecules (miR-145, miR-125b, miR-128, miR-30d) as differentiation factors to change the cellular state of mesenchymal stem cells. This molecular parameter intervention triggers oligodendrocytic differentiation, enabling the cells to transform into functional myelinating cells with altered morphology and marker expression (GalC, CNPase, MBP, O4), thereby increasing the number of effective myelinating cells from a limited stem cell source

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs the concept of copying by using miRNA molecules that can be transferred from donor cells to recipient mesenchymal stem cells. These miRNAs serve as molecular copies that carry differentiation instructions, allowing the stem cells to replicate the oligodendrocyte phenotype and function without requiring direct transplantation of adult oligodendrocyte precursors

Inventive Principle:

Principle #26Copying

2Device complexity

If conventional methods are used for oligodendrocyte generation, then the process is simple, but complete restoration of neurological deficits is not achieved

Engineering Contradiction:

Improvesimplicity of differentiation processVSAvoidcompleteness of remyelination

Core Design Contradiction:

Device complexityVSReliability

Solution Approach 1:

The patent introduces miRNA molecules as intermediary substances that mediate the differentiation process from mesenchymal stem cells to oligodendrocytes. These miRNAs (particularly miR-145 and miR-125b) act as molecular messengers that trigger and regulate the differentiation cascade, enabling reliable transformation into functional myelinating cells that can restore neurological function in disease models

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces conventional mechanical or chemical differentiation methods with a molecular biology approach using miRNA-based mechanisms. This substitution enables more precise and reliable control over the differentiation process, achieving complete remyelination in experimental models while maintaining relative simplicity through the use of small RNA molecules rather than complex culture systems

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach effectively changes the morphology and increases the expression of oligodendrocytic markers in mesenchymal stem cells, potentially leading to improved remyelination and treatment of nerve diseases by generating a population of cells with an oligodendrocyte phenotype.

Implementation Method 1

contacting mesenchymal stem cells with at least one exogenous miRNA selected from the group consisting of miR-145, miR-30d, miR-125b, miR-128, miR-181c, miR-26a, miR-196, miR-10b, miR-25, miR-424, miR19 and miR149, thereby generating the population of cells

Methodology Applied

Scientific EffectmiRNA-induced differentiation:

Implementation Method 2

downregulating connective tissue growth factor (CTGF) to promote the generation of oligodendrocyte-like cells

Methodology Applied

Scientific EffectGene downregulation:

Data Source

PatentUS9783781B2Methods of generating oligodendrocytes and cell populations comprising same

Publication Date: 2017.10.10 EXOSTEM BIOTEC LTD

AI summary

A method of generating a population of cells useful for treating a brain disorder in a subject is disclosed. The method comprises contacting mesenchymal stem cells (MSCs) with at least one exogenous miRNA having a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-19 and 27-35, thereby generating the population of cells and/or generating neurotrophic factors that may provide important signals to damaged tissues or locally residing stem cells. MSCs differentiated by miRs may also secrete miRs and deliver them to adjacent cells and therefore provide important signals to neighboring endogenous normal or malignant cells.